U.S. markets close in 6 hours 9 minutes
  • S&P 500

    3,829.08
    -2.31 (-0.06%)
     
  • Dow 30

    30,998.42
    +30.60 (+0.10%)
     
  • Nasdaq

    11,295.21
    -27.03 (-0.24%)
     
  • Russell 2000

    1,746.48
    +5.15 (+0.30%)
     
  • Crude Oil

    98.09
    -1.41 (-1.42%)
     
  • Gold

    1,760.90
    -3.00 (-0.17%)
     
  • Silver

    19.22
    +0.10 (+0.52%)
     
  • EUR/USD

    1.0191
    -0.0080 (-0.77%)
     
  • 10-Yr Bond

    2.7910
    -0.0180 (-0.64%)
     
  • GBP/USD

    1.1925
    -0.0027 (-0.22%)
     
  • USD/JPY

    135.3350
    -0.5070 (-0.37%)
     
  • BTC-USD

    20,097.87
    +613.40 (+3.15%)
     
  • CMC Crypto 200

    435.43
    -0.09 (-0.02%)
     
  • FTSE 100

    7,140.22
    +114.75 (+1.63%)
     
  • Nikkei 225

    26,107.65
    -315.82 (-1.20%)
     

What Type Of Shareholders Own The Most Number of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

A look at the shareholders of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Companies that used to be publicly owned tend to have lower insider ownership.

Rigel Pharmaceuticals is a smaller company with a market capitalization of US$292m, so it may still be flying under the radar of many institutional investors. In the chart below, we can see that institutional investors have bought into the company. Let's take a closer look to see what the different types of shareholders can tell us about Rigel Pharmaceuticals.

See our latest analysis for Rigel Pharmaceuticals

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Rigel Pharmaceuticals?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

Rigel Pharmaceuticals already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Rigel Pharmaceuticals, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Rigel Pharmaceuticals is not owned by hedge funds. FMR LLC is currently the company's largest shareholder with 14% of shares outstanding. BlackRock, Inc. is the second largest shareholder owning 9.6% of common stock, and The Vanguard Group, Inc. holds about 5.3% of the company stock.

After doing some more digging, we found that the top 11 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Rigel Pharmaceuticals

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our data suggests that insiders own under 1% of Rigel Pharmaceuticals, Inc. in their own names. It appears that the board holds about US$546k worth of stock. This compares to a market capitalization of US$292m. Many investors in smaller companies prefer to see the board more heavily invested. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public-- including retail investors -- own 17% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 1 warning sign we've spotted with Rigel Pharmaceuticals .

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.